Understanding the molecular mechanisms of friedreich's ataxia to develop therapeutic approaches

Human Molecular Genetics

Volumn 19, Issue R1, 2010, Pages

  Schmucker, Stéphane ^a,d,e   Puccio, Hélène ^a,b,c,d,e  

^a INSTITUT DE GÉNÉTIQUE ET DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

^b INSERM   (France)

^c CNRS   (France)

^d UNIVERSITÉ DE STRASBOURG   (France)

^e l'alimentation et l'Environnement   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; DEFERIPRONE; FRATAXIN; HISTONE DEACETYLASE INHIBITOR; HISTONE H3; IDEBENONE; IRON SULFUR PROTEIN; N1 (2 AMINOPHENYL) N7 (4 TOLYL)HEPTANEDIAMIDE; N1 (2 AMINOPHENYL) N7 PHENYLHEPTANEDIAMIDE; RECOMBINANT ERYTHROPOIETIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); SUCCINATE DEHYDROGENASE (UBIQUINONE); UBIQUINONE; UNCLASSIFIED DRUG;

ANTIOXIDANT ACTIVITY; ARTICLE; CHROMATIN ASSEMBLY AND DISASSEMBLY; CLINICAL TRIAL; DNA DAMAGE; FRIEDREICH ATAXIA; HEART VENTRICLE HYPERTROPHY; HETEROCHROMATIN; HUMAN; IRON CHELATION; IRON OVERLOAD; MITOCHONDRIAL ENERGY TRANSFER; MITOCHONDRIAL RESPIRATION; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; TRINUCLEOTIDE REPEAT;

FRIEDREICH ATAXIA; HUMANS; IRON-BINDING PROTEINS; MUTATION;

EID: 77953902544     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddq165     Document Type: Article

References (97)

1. Cossee, M., Schmitt, M., Campuzano, V., Reutenauer, L., Moutou, C., Mandel, J.L. and Koenig, M. (1997) Evolution of the Friedreich's ataxia trinucleotide repeat expansion: founder effect and premutations. Proc. Natl Acad. Sci. USA, 94, 7452-7457.
2. Harding, A.E. (1981) Friedreich's ataxia: a clinical and genetic study of 90 families with an analysis of early diagnostic criteria and intrafamilial clustering of clinical features. Brain, 104, 589-620.
3. Pandolfo, M. (2009) Friedreich ataxia: the clinical picture. J. Neurol., 256 (Suppl. 1), 3-8.
4. Harding, A.E. and Hewer, R.L. (1983) The heart disease of Friedreich's ataxia: a clinical and electrocardiographic study of 115 patients, with an analysis of serial electrocardiographic changes in 30 cases. Q. J. Med., 52, 489-502.
5. Campuzano, V., Montermini, L., Lutz, Y., Cova, L., Hindelang, C., Jiralerspong, S., Trottier, Y., Kish, S.J., Faucheux, B., Trouillas, P. et al. (1997) Frataxin is reduced in Friedreich ataxia patients and is associated with mitochondrial membranes. Hum. Mol. Genet., 6, 1771-1780.
6. Campuzano, V., Montermini, L., Molto, M.D., Pianese, L., Cossee, M., Cavalcanti, F., Monros, E., Rodius, F., Duclos, F., Monticelli, A. et al. (1996) Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science, 271, 1423-1427.
7. Koutnikova, H., Campuzano, V., Foury, F., Dolle, P., Cazzalini, O. and Koenig, M. (1997) Studies of human, mouse and yeast homologues indicate a mitochondrial function for frataxin. Nat. Genet., 16, 345-351.
8. Cossee, M., Durr, A., Schmitt, M., Dahl, N., Trouillas, P., Allinson, P., Kostrzewa, M., Nivelon-Chevallier, A., Gustavson, K.H., Kohlschutter, A. et al. (1999) Friedreich's ataxia: point mutations and clinical presentation of compound heterozygotes. Ann. Neurol., 45, 200-206.
9. Gellera, C., Castellotti, B., Mariotti, C., Mineri, R., Seveso, V., Didonato, S. and Taroni, F. (2007) Frataxin gene point mutations in Italian Friedreich ataxia patients. Neurogenetics, 8, 289-299.
10. Puccio, H. (2009) Multicellular models of Friedreich ataxia. J. Neurol., 256 (Suppl. 1), 18-24.
11. Ohshima, K., Montermini, L., Wells, R.D. and Pandolfo, M. (1998) Inhibitory effects of expanded GAA.TTC triplet repeats from intron I of the Friedreich ataxia gene on transcription and replication in vivo. J. Biol. Chem., 273, 14588-14595.
12. Wells, R.D. (2008) DNA triplexes and Friedreich ataxia. FASEB J., 22, 1625-1634.
13. Mariappan, S.V., Catasti, P., Silks, L.A. 3rd, Bradbury, E.M. and Gupta, G. (1999) The high-resolution structure of the triplex formed by the GAA/TTC triplet repeat associated with Friedreich's ataxia. J. Mol. Biol., 285, 2035-2052.
14. Sakamoto, N., Chastain, P.D., Parniewski, P., Ohshima, K., Pandolfo, M., Griffith, J.D. and Wells, R.D. (1999) Sticky DNA: self-association properties of long GAA.TTC repeats in R.R.Y triplex structures from Friedreich's ataxia. Mol. Cell., 3, 465-475.
15. Sakamoto, N., Ohshima, K., Montermini, L., Pandolfo, M. and Wells, R.D. (2001) Sticky DNA, a self-associated complex formed at long GAA*TTC repeats in intron 1 of the frataxin gene, inhibits transcription. J. Biol. Chem., 276, 27171-27177.
16. Bergquist, H., Nikravesh, A., Fernandez, R.D., Larsson, V., Nguyen, C.H., Good, L. and Zain, R. (2009) Structure-specific recognition of Friedreich's ataxia (GAA)n repeats by benzoquinoquinoxaline derivatives. Chembiochem, 10, 2629-2637.
17. Grabczyk, E., Mancuso, M. and Sammarco, M.C. (2007) A persistent RNA.DNA hybrid formed by transcription of the Friedreich ataxia triplet repeat in live bacteria, and by T7 RNAP in vitro. Nucleic Acids Res., 35, 5351-5359.
18. Clark, R.M., De Biase, I., Malykhina, A.P., Al-Mahdawi, S., Pook, M. and Bidichandani, S.I. (2007) The GAA triplet-repeat is unstable in the context of the human FXN locus and displays age-dependent expansions in cerebellum and DRG in a transgenic mouse model. Hum. Genet., 120, 633-640.
19. De Biase, I., Rasmussen, A., Endres, D., Al-Mahdawi, S., Monticelli, A., Cocozza, S., Pook, M. and Bidichandani, S.I. (2007) Progressive GAA expansions in dorsal root ganglia of Friedreich's ataxia patients. Ann. Neurol., 61, 55-60.
20. De Biase, I., Rasmussen, A., Monticelli, A., Al-Mahdawi, S., Pook, M., Cocozza, S. and Bidichandani, S.I. (2007) Somatic instability of the expanded GAA triplet-repeat sequence in Friedreich ataxia progresses throughout life. Genomics, 90,1-5.
21. Saveliev, A., Everett, C., Sharpe, T., Webster, Z. and Festenstein, R. (2003) DNA triplet repeats mediate heterochromatin-protein-1-sensitive variegated gene silencing. Nature, 422, 909-913.
22. Elgin, S.C. and Grewal, S.I. (2003) Heterochromatin: silence is golden. Curr. Biol., 13, R895-R898.
23. El-Osta, A. and Wolffe, A.P. (2000) DNA methylation and histone deacetylation in the control of gene expression: basic biochemistry to human development and disease. Gene Expr., 9, 63-75.
24. Herman, D., Jenssen, K., Burnett, R., Soragni, E., Perlman, S.L. and Gottesfeld, J.M. (2006) Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia. Nat. Chem. Biol., 2, 551-558.
25. Greene, E., Mahishi, L., Entezam, A., Kumari, D. and Usdin, K. (2007) Repeat-induced epigenetic changes in intron 1 of the frataxin gene and its consequences in Friedreich ataxia. Nucleic Acids Res., 35, 3383-3390.
26. De Biase, I., Chutake, Y.K., Rindler, P.M. and Bidichandani, S.I. (2009) Epigenetic silencing in Friedreich ataxia is associated with depletion of CTCF (CCCTC-binding factor) and antisense transcription. PLoS One, 4, e7914.
27. Al-Mahdawi, S., Pinto, R.M., Ismail, O., Varshney, D., Lymperi, S., Sandi, C., Trabzuni, D. and Pook, M. (2008) The Friedreich ataxia GAA repeat expansion mutation induces comparable epigenetic changes in human and transgenic mouse brain and heart tissues. Hum. Mol. Genet., 17, 735-746.
28. Rai, M., Soragni, E., Jenssen, K., Burnett, R., Herman, D., Coppola, G., Geschwind, D.H., Gottesfeld, J.M. and Pandolfo, M. (2008) HDAC inhibitors correct frataxin deficiency in a Friedreich ataxia mouse model. PLoS One, 3, e1958.
29. Phillips, J.E. and Corces, V.G. (2009) CTCF: master weaver of the genome. Cell, 137, 1194-1211.
30. Grabczyk, E. and Usdin, K. (2000) Alleviating transcript insufficiency caused by Friedreich's ataxia triplet repeats. Nucleic Acids Res., 28, 4930-4937.
31. Dervan, P.B. and Edelson, B.S. (2003) Recognition of the DNA minor groove by pyrrole-imidazole polyamides. Curr. Opin. Struct. Biol., 13, 284-299.
32. Burnett, R., Melander, C., Puckett, J.W., Son, L.S., Wells, R.D., Dervan, P.B. and Gottesfeld, J.M. (2006) DNA sequence-specific polyamides alleviate transcription inhibition associated with long GAA.TTC repeats in Friedreich's ataxia. Proc. Natl Acad. Sci. USA, 103, 11497-11502.
33. Gottesfeld, J.M. (2007) Small molecules affecting transcription in Friedreich ataxia. Pharmacol. Ther., 116, 236-248.
34. Langley, B., Gensert, J.M., Beal, M.F. and Ratan, R.R. (2005) Remodeling chromatin and stress resistance in the central nervous system: histone deacetylase inhibitors as novel and broadly effective neuroprotective agents. Curr. Drug Targets CNS Neurol. Disord., 4, 41-50.
35. Sturm, B., Stupphann, D., Kaun, C., Boesch, S., Schranzhofer, M., Wojta, J., Goldenberg, H. and Scheiber-Mojdehkar, B. (2005) Recombinant human erythropoietin: effects on frataxin expression in vitro. Eur. J. Clin. Invest., 35, 711-717.
36. Martelli, A., Wattenhofer-Donze, M., Schmucker, S., Bouvet, S., Reutenauer, L. and Puccio, H. (2007) Frataxin is essential for extramitochondrial Fe-S cluster proteins in mammalian tissues. Hum. Mol. Genet., 16, 2651-2658.
37. Muhlenhoff, U., Gerber, J., Richhardt, N. and Lill, R. (2003) Components involved in assembly and dislocation of iron-sulfur clusters on the scaffold protein Isu1p. EMBO J., 22, 4815-4825.
38. Puccio, H., Simon, D., Cossee, M., Criqui-Filipe, P., Tiziano, F., Melki, J., Hindelang, C., Matyas, R., Rustin, P. and Koenig, M. (2001) Mouse models for Friedreich ataxia exhibit cardiomyopathy, sensory nerve defect and Fe-S enzyme deficiency followed by intramitochondrial iron deposits. Nat. Genet., 27, 181-186.
39. Rotig, A., de Lonlay, P., Chretien, D., Foury, F., Koenig, M., Sidi, D., Munnich, A. and Rustin, P. (1997) Aconitase and mitochondrial iron-sulphur protein deficiency in Friedreich ataxia. Nat. Genet., 17, 215-217.
40. Babcock, M., de Silva, D., Oaks, R., Davis-Kaplan, S., Jiralerspong, S., Montermini, L., Pandolfo, M. and Kaplan, J. (1997) Regulation of mitochondrial iron accumulation by Yfh1p, a putative homolog of frataxin. Science, 276, 1709-1712.
41. Foury, F. and Cazzalini, O. (1997) Deletion of the yeast homologue of the human gene associated with Friedreich's ataxia elicits iron accumulation in mitochondria. FEBS Lett., 411, 373-377.
42. Chantrel-Groussard, K., Geromel, V., Puccio, H., Koenig, M., Munnich, A., Rotig, A. and Rustin, P. (2001) Disabled early recruitment of antioxidant defenses in Friedreich's ataxia. Hum. Mol. Genet., 10, 2061-2067.
43. Wong, A., Yang, J., Cavadini, P., Gellera, C., Lonnerdal, B., Taroni, F. and Cortopassi, G. (1999) The Friedreich's ataxia mutation confers cellular sensitivity to oxidant stress which is rescued by chelators of iron and calcium and inhibitors of apoptosis. Hum. Mol. Genet., 8, 425-430.
44. Lamarche, J.B., Cote, M. and Lemieux, B. (1980) The cardiomyopathy of Friedreich's ataxia morphological observations in 3 cases. Can. J. Neurol. Sci., 7, 389-396.
45. Duby, G., Foury, F., Ramazzotti, A., Herrmann, J. and Lutz, T. (2002) A non-essential function for yeast frataxin in iron-sulfur cluster assembly. Hum. Mol. Genet., 11, 2635-2643.
46. Seznec, H., Simon, D., Bouton, C., Reutenauer, L., Hertzog, A., Golik, P., Procaccio, V., Patel, M., Drapier, J.C., Koenig, M. et al. (2005) Friedreich ataxia: the oxidative stress paradox. Hum. Mol. Genet., 14, 463-474.
47. Jiralerspong, S., Ge, B., Hudson, T.J. and Pandolfo, M. (2001) Manganese superoxide dismutase induction by iron is impaired in Friedreich ataxia cells. FEBS Lett., 509, 101-105.
48. Tozzi, G., Nuccetelli, M., Lo Bello, M., Bernardini, S., Bellincampi, L., Ballerini, S., Gaeta, L.M., Casali, C., Pastore, A., Federici, G. et al. (2002) Antioxidant enzymes in blood of patients with Friedreich's ataxia. Arch. Dis. Child., 86, 376-379.
49. Calmels, N., Schmucker, S., Wattenhofer-Donze, M., Martelli, A., Vaucamps, N., Reutenauer, L., Messaddeq, N., Bouton, C., Koenig, M. and Puccio, H. (2009) The first cellular models based on frataxin missense mutations that reproduce spontaneously the defects associated with Friedreich ataxia. PLoS One, 4, e6379.
50. Llorens, J.V., Navarro, J.A., Martinez-Sebastian, M.J., Baylies, M.K., Schneuwly, S., Botella, J.A. and Molto, M.D. (2007) Causative role of oxidative stress in a Drosophila model of Friedreich ataxia. FASEB J., 21, 333-344.
51. Paupe, V., Dassa, E.P., Goncalves, S., Auchere, F., Lonn, M., Holmgren, A. and Rustin, P. (2009) Impaired nuclear Nrf2 translocation undermines the oxidative stress response in Friedreich ataxia. PLoS One, 4, e4253.
52. Schulz, J.B., Dehmer, T., Schols, L., Mende, H., Hardt, C., Vorgerd, M., Burk, K., Matson, W., Dichgans, J., Beal, M.F. et al. (2000) Oxidative stress in patients with Friedreich ataxia. Neurology, 55, 1719-1721.
53. Bradley, J.L., Homayoun, S., Hart, P.E., Schapira, A.H. and Cooper, J.M. (2004) Role of oxidative damage in Friedreich's ataxia. Neurochem. Res., 29, 561-567.
54. Emond, M., Lepage, G., Vanasse, M. and Pandolfo, M. (2000) Increased levels of plasma malondialdehyde in Friedreich ataxia. Neurology, 55, 1752-1753.
55. Di Prospero, N.A., Baker, A., Jeffries, N. and Fischbeck, K.H. (2007) Neurological effects of high-dose idebenone in patients with Friedreich's ataxia: a randomised, placebo-controlled trial. Lancet Neurol., 6, 878-886.
56. Di Prospero, N.A., Sumner, C.J., Penzak, S.R., Ravina, B., Fischbeck, K.H. and Taylor, J.P. (2007) Safety, tolerability, and pharmacokinetics of high-dose idebenone in patients with Friedreich ataxia. Arch. Neurol., 64, 803-808.
57. Myers, L., Farmer, J.M., Wilson, R.B., Friedman, L., Tsou, A., Perlman, S.L., Subramony, S.H., Gomez, C.M., Ashizawa, T., Wilmot, G.R. et al. (2008) Antioxidant use in Friedreich ataxia. J. Neurol. Sci., 267, 174-176.
58. Myers, L.M., Lynch, D.R., Farmer, J.M., Friedman, L.S., Lawson, J.A. and Wilson, R.B. (2008) Urinary isoprostanes in Friedreich ataxia: lack of correlation with disease features. Mov. Disord., 23, 1920-1922.
59. Haugen, A.C., Di Prospero, N.A., Parker, J.S., Fannin, R.D., Chou, J., Meyer, J.N., Halweg, C., Collins, J.B., Durr, A., Fischbeck, K. et al. Altered gene expression and DNA damage in peripheral blood cells from Friedreich's ataxia patients: cellular model of pathology. PLoS Genet., 6, e1000812.
60. Rudolf, J., Makrantoni, V., Ingledew, W.J., Stark, M.J. and White, M.F. (2006) The DNA repair helicases XPD and FancJ have essential iron- sulfur domains. Mol. Cell, 23, 801-808.
61. Cooper, J.M. and Schapira, A.H. (2003) Friedreich's ataxia: disease mechanisms, antioxidant and coenzyme Q10 therapy. Biofactors, 18, 163-171.
62. Cooper, J.M. and Schapira, A.H. (2007) Friedreich's ataxia: coenzyme Q10 and vitamin E therapy. Mitochondrion, 7 (suppl.), S127-S135.
63. Rustin, P., Rotig, A., Munnich, A. and Sidi, D. (2002) Heart hypertrophy and function are improved by idebenone in Friedreich's ataxia. Free Radic. Res., 36, 467-469.
64. Seznec, H., Simon, D., Monassier, L., Criqui-Filipe, P., Gansmuller, A., Rustin, P., Koenig, M. and Puccio, H. (2004) Idebenone delays the onset of cardiac functional alteration without correction of Fe-S enzymes deficit in a mouse model for Friedreich ataxia. Hum. Mol. Genet., 13, 1017-1024.
65. Gillis, J.C., Benefield, P. and McTavish, D. (1994) Idebenone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in age-related cognitive disorders. Drugs Aging, 5, 133-152.
66. Hart, P.E., Lodi, R., Rajagopalan, B., Bradley, J.L., Crilley, J.G., Turner, C., Blamire, A.M., Manners, D., Styles, P., Schapira, A.H. et al. (2005) Antioxidant treatment of patients with Friedreich ataxia: four-year follow-up. Arch. Neurol., 62, 621-626.
67. Pandolfo, M. (2008) Drug insight: antioxidant therapy in inherited ataxias. Nat. Clin. Pract. Neurol., 4, 86-96.
68. Sohn, Y.S., Breuer, W., Munnich, A. and Cabantchik, Z.I. (2008) Redistribution of accumulated cell iron: a modality of chelation with therapeutic implications. Blood, 111, 1690-1699.
69. Boddaert, N., Le Quan Sang, K.H., Rotig, A., Leroy-Willig, A., Gallet, S., Brunelle, F., Sidi, D., Thalabard, J.C., Munnich, A. and Cabantchik, Z.I. (2007) Selective iron chelation in Friedreich ataxia: biologic and clinical implications. Blood, 110, 401-408.
70. Condo, I., Ventura, N., Malisan, F., Rufini, A., Tomassini, B. and Testi, R. (2007) In vivo maturation of human frataxin. Hum. Mol. Genet., 16, 1534-1540.
71. Koutnikova, H., Campuzano, V. and Koenig, M. (1998) Maturation of wild-type and mutated frataxin by the mitochondrial processing peptidase. Hum. Mol. Genet., 7, 1485-1489.
72. Schmucker, S., Argentini, M., Carelle-Calmels, N., Martelli, A. and Puccio, H. (2008) The in vivo mitochondrial two-step maturation of human frataxin. Hum. Mol. Genet., 17, 3521-3531.
73. Adinolfi, S., Trifuoggi, M., Politou, A.S., Martin, S. and Pastore, A. (2002) A structural approach to understanding the iron-binding properties of phylogenetically different frataxins. Hum. Mol. Genet., 11, 1865-1877.
74. Cook, J.D., Bencze, K.Z., Jankovic, A.D., Crater, A.K., Busch, C.N., Bradley, P.B., Stemmler, A.J., Spaller, M.R. and Stemmler, T.L. (2006) Monomeric yeast frataxin is an iron-binding protein. Biochemistry, 45, 7767-7777.
75. He, Y., Alam, S.L., Proteasa, S.V., Zhang, Y., Lesuisse, E., Dancis, A. and Stemmler, T.L. (2004) Yeast frataxin solution structure, iron binding, and ferrochelatase interaction. Biochemistry, 43, 16254-16262.
76. Nair, M., Adinolfi, S., Pastore, C., Kelly, G., Temussi, P. and Pastore, A. (2004) Solution structure of the bacterial frataxin ortholog, CyaY: mapping the iron binding sites. Structure, 12, 2037-2048.
77. Dhe-Paganon, S., Shigeta, R., Chi, Y.I., Ristow, M. and Shoelson, S.E. (2000) Crystal structure of human frataxin. J. Biol. Chem., 275, 30753-30756.
78. Musco, G., Stier, G., Kolmerer, B., Adinolfi, S., Martin, S., Frenkiel, T., Gibson, T. and Pastore, A. (2000) Towards a structural understanding of Friedreich's ataxia: the solution structure of frataxin. Structure, 8, 695-707.
79. Pandolfo, M. and Pastore, A. (2009) The pathogenesis of Friedreich ataxia and the structure and function of frataxin. J. Neurol., 256 (Suppl. 1), 9-17.
80. Gerber, J., Muhlenhoff, U. and Lill, R. (2003) An interaction between frataxin and Isu1/Nfs1 that is crucial for Fe/S cluster synthesis on Isu1. EMBO Rep., 4, 906-911.
81. Gonzalez-Cabo, P., Vazquez-Manrique, R.P., Garcia-Gimeno, M.A., Sanz, P. and Palau, F. (2005) Frataxin interacts functionally with mitochondrial electron transport chain proteins. Hum. Mol. Genet., 14, 2091-2098.
82. Shan, Y., Napoli, E. and Cortopassi, G. (2007) Mitochondrial frataxin interacts with ISD11 of the NFS1/ISCU complex and multiple mitochondrial chaperones. Hum. Mol. Genet., 16, 929-941.
83. Yoon, T. and Cowan, J.A. (2004) Frataxin-mediated iron delivery to ferrochelatase in the final step of heme biosynthesis. J. Biol. Chem., 279, 25943-25946.
84. Bulteau, A.L., O'Neill, H.A., Kennedy, M.C., Ikeda-Saito, M., Isaya, G. and Szweda, L.I. (2004) Frataxin acts as an iron chaperone protein to modulate mitochondrial aconitase activity. Science, 305, 242-245.
85. Adinolfi, S., Iannuzzi, C., Prischi, F., Pastore, C., Iametti, S., Martin, S.R., Bonomi, F. and Pastore, A. (2009) Bacterial frataxin CyaY is the gatekeeper of iron-sulfur cluster formation catalyzed by IscS. Nat. Struct. Mol. Biol., 16, 390-396.
86. Layer, G., Ollagnier-de Choudens, S., Sanakis, Y. and Fontecave, M. (2006) Iron-sulfur cluster biosynthesis: characterization of Escherichia coli CYaY as an iron donor for the assembly of [2Fe-2S] clusters in the scaffold IscU. J. Biol. Chem., 281, 16256-16263.
87. Leidgens, S., De Smet, S. and Foury, F. Frataxin interacts with Isu1 through a conserved tryptophan in its beta-sheet. Hum. Mol. Genet., 19, 276-286.
88. Li, H., Gakh, O., Smith, D.Y.t. and Isaya, G. (2009) Oligomeric yeast frataxin drives assembly of core machinery for mitochondrial iron-sulfur cluster synthesis. J. Biol. Chem., 284, 21971-21980.
89. Wang, T. and Craig, E.A. (2008) Binding of yeast frataxin to the scaffold for Fe-S cluster biogenesis, Isu. J. Biol. Chem., 283, 12674-12679.
90. Lill, R. (2009) Function and biogenesis of iron-sulphur proteins. Nature, 460, 831-838.
91. O'Neill, H.A., Gakh, O. and Isaya, G. (2005) Supramolecular assemblies of human frataxin are formed via subunit-subunit interactions mediated by a non-conserved amino-terminal region. J. Mol. Biol., 345, 433-439.
92. O'Neill, H.A., Gakh, O., Park, S., Cui, J., Mooney, S.M., Sampson, M., Ferreira, G.C. and Isaya, G. (2005) Assembly of human frataxin is a mechanism for detoxifying redox-active iron. Biochemistry, 44, 537-545.
93. Gakh, O., Smith, D.Y.t. and Isaya, G. (2008) Assembly of the iron-binding protein frataxin in Saccharomyces cerevisiae responds to dynamic changes in mitochondrial iron influx and stress level. J. Biol. Chem., 283, 31500-31510.
94. Karlberg, T., Schagerlof, U., Gakh, O., Park, S., Ryde, U., Lindahl, M., Leath, K., Garman, E., Isaya, G. and Al-Karadaghi, S. (2006) The structures of frataxin oligomers reveal the mechanism for the delivery and detoxification of iron. Structure, 14, 1535-1546.
95. Schagerlof, U., Elmlund, H., Gakh, O., Nordlund, G., Hebert, H., Lindahl, M., Isaya, G. and Al-Karadaghi, S. (2008) Structural basis of the iron storage function of frataxin from single-particle reconstruction of the iron-loaded oligomer. Biochemistry, 47, 4948-4954.
96. Aloria, K., Schilke, B., Andrew, A. and Craig, E.A. (2004) Iron-induced oligomerization of yeast frataxin homologue Yfh1 is dispensable in vivo. EMBO Rep., 5, 1096-1101.
97. Rouault, T.A. and Tong, W.H. (2008) Iron-sulfur cluster biogenesis and human disease. Trends Genet., 24, 398-407.